Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.22 USD | +9.75% | +4.85% | +39.80% |
May. 23 | Cogent Reports Positive Cancer Combo Treatment Trial Data; Names Commercial Chief | MT |
May. 23 | Cogent Biosciences, Inc. Announces the Appointment of Cole Pinnow as Chief Commercial Officer | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+39.80% | 786M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-0.29% | 22.1B | |
-9.28% | 18.34B | |
-41.70% | 16.59B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- COGT Stock
- News Cogent Biosciences, Inc.
- Cogent Biosciences Says Bezuclastinib Shows Overall Response Rate of 73% in Advanced Systemic Mastocytosis Phase 2 Trial